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We reviewed and analyzed the relationship between physical exercise and inflammatory bowel disease (IBD) which covers a group
of chronic, relapsing, and remitting intestinal disorders including Crohn’s disease (CD) and ulcerative colitis. The etiology of IBD
likely involves a combination of genetic predisposition and environmental risk factors. Physical training has been suggested to be
protective against the onset of IBD, but there are inconsistencies in the findings of the published literature. Hypertrophy of the
mesenteric white adipose tissue (mWAT) is recognized as a characteristic feature of CD, but its importance for the perpetuation of
onset of this intestinal disease is unknown. Adipocytes synthesize proinflammatory and anti-inflammatory cytokines. Hypertrophy
of mWAT could play a role as a barrier to the inflammatory process, but recent data suggest that deregulation of adipokine secretion
is involved in the pathogenesis of CD. Adipocytokines and macrophage mediators perpetuate the intestinal inflammatory process,
leading tomucosal ulcerations along themesenteric border, a typical feature of CD. Contracting skeletalmuscles release biologically
active myokines, known to exert the direct anti-inflammatory effects, and inhibit the release of proinflammatory mediators from
visceral fat. Further research is required to confirm these observations and establish exercise regimes for IBD patients.
1. Introduction
Chronic inflammation plays a central role in the pathology
of many diseases. For some, such as rheumatoid arthritis
(RA), inflammatory bowel diseases (IBD), and asthma, the
most characteristic is a massive infiltration of inflammatory
cells at the site of disease activity and the local presence of
inflammatory mediators in elevated concentrations as well
as their abundance in the systemic circulation. These may
lead to pathological disorders in organs distant from the
primary inflammatory lesions probably evoked by systemic
inflammatory mediators [1].
Ulcerative colitis (UC) and Crohn’s disease (CD) are the
two main forms of IBD characterized by a cyclic nature,
alternating between active and quiescent states impairing
patients’ quality of life. Although the inflammatory process
in CD is typically transmural and can affect any part of the
gastrointestinal tract, theUC affects only the colon and is lim-
ited to the mucosa and superficial submucosa [2]. Anorexia,
malnutrition, altered body composition, and development
of mesenteric white adipose tissue (mWAT) hypertrophy
(accumulation of intra-abdominal mWAT) are other well-
known features of IBD and especially of CD [2]. Additionally,
apart from intestinal changes in CD, the secondary disorders
in distant organs such as skin lesion, arthritis, osteoporosis,
eye, and liver disorders may frequently occur [2]. Association
between inflammation and carcinogenesis is well proven and
IBD is an important risk factor for the development of colon
cancer [3]. Although progress has been made in under-
standing the IBD, its etiology is still unknown. The accepted
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theory suggests that a combination of environmental agents
and a dysfunctional mucosal immune system in genetically
susceptible individuals could lead to the development of
either CD or UC [4, 5]. It was established that CD is a Th1
cytokine-mediated disease characterized by increased pro-
duction of interferon (IFN-) 𝛾, whereas UC most likely
resembles a modified Th2 profile, characterized by increased
production of interleukin- (IL-) 5 production and normal
IFN-𝛾 production [6]. Cytokines, such as TNF-𝛼, IL-1𝛽, and
IL-6 are more promiscuous in their function because they
are associated with both forms of IBD to a lesser or greater
degree [6, 7]. Each of these cytokines can activate NF-𝜅B and
the mitogen-activated protein kinases, thereby initiating a
cascade of “downstream”proinflammatory effects that are the
immediate prerequisites of tissue and organ pathology in IBD
[6]. Recently, TNF-like weak inducer of apoptosis (TWEAK),
the TNF super family (TNFSF) member, has appeared as a
new factor in the inflammatory processes and its crucial role
in IBD has been proposed [8–10]. Its actions are mediated
by binding to fibroblast growth factor-inducible 14 (Fn14),
surface receptor that has been linkedto several intracellular
signaling pathways, including the nuclear factor-𝜅B (NF-
𝜅B) inflammatory pathway [11]. Fn14 can be upregulated on
intestinal epithelial cells, most probably by their exposure
to microbial or inflammatory products and contribute to
failure of the mucosal barrier; the induction of IEC-derived
mediators that promote chronic inflammation and shape gut
immunity against commensally bacteria [9]. Interestingly,
this expression of Fn14 is upregulated in CD patients [11].
The concept of exercise training could cover heteroge-
neous interventions that differ in type (e.g., endurance versus
resistance training, acute versus chronic exercise), intensity,
frequency, and duration. Structured exercise training could
consist of aerobic exercise, resistance training, or a combi-
nation of both. In contrast to structured exercise training,
physical activity is defined as any bodily movement produced
by skeletal muscle contractions resulting in increased energy
expenditure [12].
The well-documented observations that physical activity
is inversely correlated with systemic low-level inflamma-
tion lead to suggestion that the anti-inflammatory activity
induced by regular exercise may be responsible for some
beneficial health effects in patients with chronic diseases [13].
However, the intensive exercise may induce a transient mild
systemic inflammation and increased level of cytokines and
these adverse effects depend on intensity and duration of
exercise. Following prolonged and strenuous exercise, the
function of the immune system is impaired for several hours
[14, 15], but on the other hand, the regular exercise training
has been shown to increase resistance to infections [16–19].
The possible beneficial effects of physical activity on the
gastrointestinal tract have been so far little studied. It is
known that intensive exercise such as long distance running
and triathlons could cause nausea, heartburn, diarrhea, or
even gastrointestinal bleeding and marathon runners suffer
from “runner’s ischemic colitis,” involving bloody diarrhea,
fatigue, and fever [20].The involvement of physical activity in
prevention of colon cancer [21] has been well proven, but the
effect of physical activity on IBD is less documented and the
importance of exercise as adjunct anti-inflammatory therapy
has been suggested [22–24]. There is a general commit-
ment that IBD patients could benefit from physical training
because regular exercise could improve psychological health
and reduce some disease symptoms and complications [25].
However, from our current knowledge on exercise in relation
to immune functions, cytokines network, and in particular,
the secretory role of contracting muscles, one concludes that
a relatively small attention has been addressed tomechanisms
of action of regular exercise in patients with a chronic
inflammatory disease like IBD, in which immune response is
impaired. Most studies have examined the beneficial effects
of exercise in terms of quality of life and general fitness
but relatively few studied effects of training on disease
pathogenesis and measures of inflammation and evidence-
based recommendations could not yet be made for this
disease [22–25].
Taking into the account the lack of sufficient evidence-
based exercise guidelines for those subjects who suffer from
IBD and that physical activity is recommended for such
patients as a complementary medical therapy, the purpose of
the review was to evaluate published human and experimen-
tal research studies focusing on physical activity and IBD.
Particular aims of the present review were to update
the literature on physical activity in IBD and to evaluate
(1) whether physical activity in the preillness period could
influence onset of IBD, (2) impact of exercise on IBD, and
(3) overview on selection of types and intensities of exercise
in individuals suffering from this disease and how exercise
affects experimental models of this disease. In discussion,
we focused on potential mechanisms of beneficial action of
physical training.
2. Methods
2.1. Search Strategy. We searched the following electronic
databases up to January 2014: MEDLINE (accessed by
PubMed), Google Scholar, Web of Science, PEDRo, and IBD/
FBD Group Specialized Register (June 2013). The follow-
ing search string was entered into each database using
MeSH terms, appropriate alternatives, and Boolean opera-
tors: inflammatory bowel disease, Crohn’s disease, or ulcer-
ative colitis and exercise, physical activity, physical fitness, or
physical training. Variations of the above search strategy were
used to search the databases other than Medline.
2.2. Study Selection. Two reviewers (JB and TB) indepen-
dently assessed study eligibility and the full-text articles
were then examined. Bibliographies from existing articles
were screened manually. Only fully published papers were
reviewed. Figure 1 provides a flowchart of study selection. In
Figure 2, the insight into mechanism of crosstalk between
skeletal muscle, adipose tissue and the inflammation in the
gut is presented.
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Figure 1: Flowchart for selection of studies.
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Figure 2: Crosstalk between skeletal muscle, adipose tissue, and intestinal inflammation.
3. Results
3.1. Exercise in the Preillness Period. The incidence and
prevalence of IBD rapidly increased in last years in developed
countries and the rise witnessed in the rest of the world
closely correlates with adopting a western lifestyle [26].
These observations support the notion that a variety of envi-
ronmental factors contribute to the pathogenesis of intestinal
diseases [26]. In developed countries, peoples’ lifestyle has
changed significantly, being affected by serious modifications
in dietary habits andphysical inactivity [27].Those changes in
lifestylemay have a bearing on the course of the disease. Some
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Table 1: Characteristics of studies assessing the impact of physical activity on onset of IBD included in review.
Reference Number of subjects Study characteristics Study outcome
Sonnenberg, 1990 [28] 12 014 Retrospective study (Germany)
Occupations characterized by
outdoor physical work appeared to
be protective compared with those
occupations classified as sedentary
against the onset of IBD
Persson et al., 1993 [29]
152 CD
145 UC
305 controls
Postal questionnaire (Sweden, Stockholm
County)
CD onset (but not UC) inversely
related to weekly and daily exercise
five years before disease onset
Boggild et al., 1996 [30] 2 273 872
A cohort, comprising male and female aged
20–59 (January 1986), was followed up for
hospitalizations due to chronic IBD until
December 31, 1990 (Denmark)
Sedentary office work may
contribute to IBD onset
Klein et al., 1998 [31]
55 UC
33 with CD
76 population
and 68 clinic controls
Preillness lifestyle patterns compared among
recently diagnosed IBD patients and
matched population and clinic controls
(Israel)
IBD patients had lower levels of
physical activity during their
preillness period compared to clinic
but not population controls
Cucino and Sonnenberg, 2001 [32] 2399 CD and2419 UC
Examined the occupations of IBD
mortalities 1991–1996 (USA)
IBD mortality was low in
occupations associated with manual
work and relatively high in
sedentary occupations in both CD
and UC
Halfvarson et al., 2006 [33]
Discordant twin pairs
102 CD
125 UC
Population-based twin cohort using the
cotwin control method through a postal
questionnaire (Sweden, Denmark)
No significant difference found in
physical activity between twins pairs
Chan et al., 2013 [34] 300 724
Anthropometric measurements of height
and weight plus physical activity and total
energy intake from validated questionnaires
taken at recruitment. The cohort was
monitored identifying participants who
developed either CD or UC (European
Prospective Investigation into Cancer and
Nutrition study.).
No association was found between
physical activity and onset of IBD
Hlavaty et al., 2013 [35]
190 CD
148 UC
355 controls
Case-control study through questionnaire
(Slovakia)
CD and UC associated with less
than two sporting weekly activities
Khalili et al., 2013 [36] 194 and 711 women
Women enrolled in this prospective cohort
study provided data on physical activity
since 1984 in the Nurses’ Health Study and
1989 in the Nurses’ Health Study II and
followed up through 2010 (USA).
Physical activity was inversely
associated with risk of Crohn’s
disease but not of ulcerative colitis
studies have examined the effect of lifestyle and particularly
physical activity as supposed by causal agents for the onset of
IBD (Table 1).
The protective role of physical activity against the onset
of IBD was first postulated by Sonnenberg [28] who found
that occupations characterized by outdoor physical work
appeared to be protective compared with those occupations
classified as sedentary in retrospective study in male and
female German workers. In small (𝑛 = 725) case-control
study Persson et al. [29] reported an inverse association
between physical activity and CD (but not UC) onset in
a Swedish cohort. A prospective study which followed two
cohorts, each of more than 2.3 million persons in Denmark,
for 5 or 10 years, found a small association between sedentary
office work lifestyle and the onset of IBD [30]. In 1998, a study
by Klein et al. [31] determined that IBD patients (𝑛 = 88)
had lower levels of physical activity during their preillness
period than clinic controls (𝑛 = 68; 𝑃 < 0.001). IBD patients
had lower levels of physical activity during their preillness
period compared to clinic but not population controls.
Cucino and Sonnenberg [32] examined the occupations of
IBD mortalities between 1991 and 1996 in 2399 CD and 2419
UC patients in USA and found that IBDmortality was low in
occupations associated with manual work and relatively high
in sedentary occupations.WhenHalfvarson et al. [33] studied
environmental factors in a population-based Swedish-Danish
BioMed Research International 5
Table 2: Characteristics of interventional studies examining the impact of exercise on IBD.
Reference Sample Disease type Intervention Duration of exerciseprogram Outcome
Robinson et
al., 1998 [122]
117 patients:
60 exercise
57 control
CD
Home based low impact
exercises program of
increasing intensity focused
on the hip and lumbar
regions
Twice a week (at least 10
monthly), 12 months
Bone mineral density
increased in compliant
patients in the lumbar spine
and the hip
D’Inca` et al.,
1999 [42]
6 patients in
remission
6 control
CD Acute exercise at 60% ofVO2max (cycle ergometer)
One hour
Exercise did not elicit
subjective symptoms or
changes in intestinal
permeability and lipid
peroxidation
Loudon et al.,
1999 [38]
12 patients with
inactive or
mildly active
disease
CD
Low-intensity walking
program subjects walked an
average of 2.9 sessions/wk,
at an average of
32.6min/session, and for an
average distance of
3.5 km/session
A thrice weekly, 12 wk
walking program
Stress diminished, physical
health, general well-being,
and quality of life improved
without disease exacerbation
Elsenbruch et
al., 2005 [139]
30 patients with
inactive disease
30 control
UC
60 h training program:
stress management
program, light exercise
10 weeks;
6 h/week
Improvement in quality of life
in patients with UC in
remission, while no effects of
therapy on clinical or
physiological parameters were
found
Ng et al.,
2007 [39]
16 patients with
inactive disease
16 patients
control
CD
Low-intensity walking
30min at 60% of maximum
heart rate
3 times per week during 3
months
Improvement in quality of life
and reductions in CD
symptoms
Ploeger et al.,
2012 [44]
15 pediatric
patients in
remission
15 controls
CD
Moderate intensity
continuous exercise
(MICE)
High intensity intermittent
exercise (HIIE)
30min of cycling at 50% of
peak mechanical power
(PMP) 6 bouts of 4 × 15-s of
cycling at 100% PMP
No significant exacerbation of
the disease or inflammatory
cytokine responses in both
types of exercise
Chan et al.,
2014 [45]
918 IBD patients
(54% CD and
46% UC)
CD, UC UK online survey regardingexercise habits Regular exercise
72% reported that exercise
made them feel better, but
80% had to stop exercising
temporarily or permanently at
some point because of the
severity of their symptoms
twin cohort using the cotwin control method, they found no
significant differences between the twins in physical activity
before the diagnosis of IBD.
In a recent the European Prospective Investigation into
Cancer and Nutrition study, 300,724 participants were re-
cruited into and the cohort was monitored identifying par-
ticipants who developed CD or UC, but physical activity did
not show any associationwithUC or CD [34]. In case-control
study in Slovakia [35] which included 338 patients (190 CD,
148 UC) and 355 controls CD and UC, an onset of IBD was
inversely associated with physical activity. In another recent
study in two large prospective cohorts of US women (194 711
women) the association between physical activity and risk
of ulcerative colitis and Crohn’s disease was studied [36].
Women enrolled in this prospective cohort study provided
data on physical activity since 1984 in Nurses’ Health Study
and 1989 in Nurses’ Health Study II and followed up through
2010 (USA). Physical activity was found inversely associated
with risk of Crohn’s disease but not of ulcerative colitis.
The physical activity in preillness period was shown to
reduce risk of the onset of IBD and this reduction was found
to be stronger for CD than UC [29, 36].
3.2. Impact of Exercise on IBD. The physical activity has
been used in IBD as an adjunctive therapy regime, although
the effectiveness of exercise on disease activity has not been
well described and the mechanisms of its potential beneficial
effects are poorly understood [25, 37]. Studies that examined
the effect of exercise on IBD involved mainly patients with
quiescent state of disease (Table 2). In sedentary patients with
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inactive or mildly active CD, the moderate exercise by means
of walking program or yoga led to significant improvement
in measures of quality of life and stress levels [38–41].
The moderate-intensity exercise was well tolerated by IBD
patients who are in remission and did not provoke subjective
symptoms or changes in gastrointestinal parameters [42, 43].
Ploeger et al. [44] tested the effect of moderate intensity
continuous exercise and high intensity intermittent exercise
in youth with CD and concluded that such patients can
engage in different types of exercise without a significant
exacerbation of the disease. The results of the UK online
survey have shown that a majority of respondents were
undertaking regular exercisewhichwas found to be beneficial
for the symptoms of IBD. However, most of the respondents
were prone to stop exercising at some point because of their
increased incidents of complaints on severity of symptoms
[45].
3.3. Intestinal Disorders and Physical Activity in Experimental
Animals. Some of these aspects were also observed at exper-
imental conditions because in mouse model of colitis, the
forced treadmill exercise training exacerbated inflammation
and increased mortality, while voluntary wheel training was
protective in this rodent model [46]. This effect of treadmill
exercise was accompanied by increased morbidity due to
excessive diarrhea episodes and mortality [46]. In contrast,
thirty days of voluntary wheel running attenuated inflamma-
tory gene expression in the distal colon reduced the diarrhea
incidences and protected mice from colitis-induced morbid-
ity [42]. Moreover, the induction of experimental colitis by
TNBS or dextran sulfide administration caused a significant
increase in the TNF-content in the colonic mucosa and
submucosa [47, 48]. In another study, the long-term physical
exercise of 6-week running attenuated the colonic TNF-𝛼
protein content indicating an anti-inflammatory impact of
exercise training [49]. Some studies have shown that both
forced treadmill and voluntary wheel exercise training can
exert an anti-inflammatory effect in the inflamed colon [48–
51]. In study by Saxena et al. [48] exercise training (tread-
mill running at gradually increasing speeds 10, 12, 16, and
18m/min and a 5% incline for 20min) significantly decreased
proinflammatory cytokines in the adiponectin knockout
mice with dextran sodium sulfate induced experimental
colitis. In another study moderate exercise (30min per day
of swimming) attenuated chronic stress-induced intestinal
barrier dysfunction in mice, possibly due to augmentation
of antimicrobial responses in the small intestine [52]. A
summary of experimental studies on the experimental IBD
and exercise depending on its intensity is shown in Table 3.
4. Discussion
These findings point to the important role for exercise in the
adjunct treatment of IBD in humans. Since IBD affects up to
0.25% of theUS population or∼750.000 people; thus it is con-
sidered as a significant problem [53]. The fact that selection
of a proper dosage of the exercise was able to alleviate colitis
symptoms, reduce colon inflammation, and counteract the
adverse effects associated with pharmacological therapy (e.g.,
5-aminosalicylic acid) [47–49] seems to be of key interest
in convincing medical professionals to adopt the life style
strategy as an adjunct therapy in their IBD treatment.
The protective effect of exercise may to some extent be
attributed to its anti-inflammatory effect and it may mediate
via muscle-derived peptides, the so-called “myokines” [54].
Contracting skeletal muscles release myokines like IL-15 with
endocrine effects,mediating direct anti-inflammatory effects,
and/or specific effects on visceral fat [54]. Possible role of a
new myokine irisin which is released during exercise and act
on the white fat cells is still studied [54].
Creeping fat in patients with Crohn’s disease refers to
hypertrophy of the mesenteric fat tissue located around the
inflamed parts of the intestine [55] and recent research
suggests that this fat wrapping contribute actively to disease
severity and may influence onset of complications [56–
63]. Accumulating evidence suggests that mesenteric white
adipose tissue (mWAT), composed of not only fat but also
macrophages and T lymphocytes, plays an important role as
the source of inflammation and releases various inflamma-
tory factors such as cytokines and chemokines [64–68]. This
mesenteric fat which is present from the onset of disease is
associated with overexpression of TNF-𝛼, leptin, and other
adipokines and correlates with the severity of intestinal
inflammation and tissue injury, suggesting an important role
for adipose tissue in the intestinal inflammatory process in
CD [55, 62, 69–71]. The intestinal luminal leptin, a cytokine
produced by adipocytes, is increased in CD and can upreg-
ulate NF-𝜅B expression in colonic epithelial cells [58, 72–
74]. Leptin is considered to be a proinflammatory cytokine
[58] and directly regulates production of several cytokines,
particularly those released from T cells. It increases IL-2 and
interferon 𝛾 production while decreasing IL-4 levels [58].
An overexpression of leptin mRNA in mWAT was reported
in IBD patients, indicating that leptin might participate in
the inflammatory process by enhancing mesenteric TNF-𝛼
expression [75, 76] and leptin levels have been shown to
be significantly higher in mesenteric adipose tissue from
CD patients, than in patients with noninflammatory disease
[58, 72]. Experimental colitis in rats resulted in elevated
circulating leptin levels which correlate with the degree of
inflammation and the development of anorexia [77] and
leptin antagonist ameliorated the development of chronic
experimental colitis [78]. Another adipokine, adiponectin,
which is considered anti-inflammatory, has a structure simi-
lar to TNF-𝛼 but antagonizes its effects by reducing secretion
and attenuating the biological actions by competing for
the receptor [79–81]. Divergent data have been presented
about circulating levels of adiponectin in patients with IBD
[72, 74, 80, 82–86]. Adiponectin production is enhanced in
hypertrophied mWAT which remained in contact with the
intestine of CD patients, and this increase may be specifically
related to inflammation and the presence of this fat wrapping
[79, 87]. A role for hypertrophied mesenteric fat tissue as
a barrier to the inflammatory process was postulated in
other studies [86, 88, 89]. However, recent observations of
lower levels of serum and mesenteric adiponectin in active
CD patients compared with those in remission suggest a
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Table 3: Characteristics of animal studies examining effects of exercise on experimental colitis.
Reference Species Study characteristics Study outcome
Cook et al.,
2013 [46] Male C57Bl/6J mice
Mice were randomly assigned to 3 groups:
(1) sedentary, (2) moderate intensity forced
treadmill exercise (FTR) (8–12m/min,
40min, 6 weeks, and 5x/week), or (3)
voluntary wheel training (VWR) (30 days
access to wheels). Dextran sodium sulfate
(DSS) was given at 2% (w/v) in drinking
water over 5 days. Mice discontinued
exercise 24 h prior to DSS treatment.
Forced treadmill exercise exacerbated the
colitis manifestation and mucosal
inflammation (rise in diarrhea and gene
expression of IL-6, IL-1𝛽, and IL-17 in the
colon. Also higher mortality was observed in
the FTR/DSS group. VWR alleviated colitis
symptoms and reduced inflammatory gene
expression in the colonic mucosa of
DSS-treated mice.
Saxena et al.,
2012 [48]
Male adiponectin
knockout (APNKO)
and wild type (WT)
mice (C57BL/6)
APNKO andWT mice were randomly
assigned to different groups: (1) sedentary
(SED); (2) exercise trained (ET); (3)
sedentary with dextran sodium sulfate
(DSS) treatment (SED + DSS); and (4)
exercise trained with DSS (ET + DSS).
Exercise-trained mice ran at 18m/min for
60min, 5 d/wk for 4 weeks. Subsequently,
the ET + DSS and the SED + DSS mice
received 2% DSS in their drinking water for
5 days (d), followed by 5 d of regular water.
The clinical symptoms of colitis were
unaffected by exercise and there was no
difference between the APNKO and WT mice.
The clinical symptoms of the DSS-treated
APNKOmice were worse than WT mice
treated with DSS and had increased local
STAT3 activation, higher IL-6, TNF-𝛼, IL-1𝛽,
and IL-10. Exercise training significantly
decreased proinflammatory cytokines
including IL-6, TNF-𝛼, and IL-1𝛽 and the
phosphorylation expression of STAT3 in both
WT and APNKOmice in DSS + EX.
Hoffman-
Goetz et al.,
2010 [49]
Female C57BL/6 mice
Animals were given 16 weeks of wheel
running (WR) or a control condition and at
the end of training were assigned to a single
acute treadmill exercise session (30min at
22m/min, 30min at 25m/min, and 30min
at 28m/min).
WR mice had lower TNF-𝛼 and caspase 7 and
higher IL-10 and IL-6 expression in intestinal
lymphocyte (ILymph) than NoWR mice. A
single exposure to intense aerobic treadmill
exercise increased pro-(TNF-𝛼) and
anti-(IL-10) inflammatory cytokine and
proapoptotic protein (caspase 3) expression in
ILymph. The percent of early and late apoptotic
and dead ILymph were higher after acute
exercise.
Luo et al.,
(2013) [52] Male Balb/c mice
Effect of moderate exercise (30min per day
swimming) on repeated restraint stress-
(RRS-) induced intestinal barrier
dysfunction.
Exercise attenuated chronic stress-induced
intestinal barrier dysfunction in mice, possibly
due to augmentation of antimicrobial
responses in the small intestine.
defective regulation of anti-inflammatory pathways in CD
pathogenesis [80]. The impaired balance between proinflam-
matory and anti-inflammatory factors due to an increase
in secretion of TNF-𝛼, leptin, and the release of chemoat-
tractant protein-1 (MCP-1) and the decreased production
of adiponectin could result in macrophage accumulation
in adipocytes and an inflammatory transformation of the
visceral adipose tissue, leading to the appearance of creeping
fat [88]. Adipocytokines and macrophage mediators secreted
by the creeping fat could further increase the intestinal
inflammatory process, leading to mucosal ulcerations along
the mesenteric border, a typical feature of CD [82, 90].
The massive cytokine production in the inflamed colon, in
addition to translocalizing bacteria, could further induce the
production of proinflammatory mediators in the adjacent
adipose tissue, thus inducing a vicious cycle, in which
inflammatory conditions in the intestine and the mesenteric
fat support each other [88, 91]. Cytokine overproduction and
particularly leptin by mesenteric fat could lead to anorexia,
another feature present in CD [86].
4.1. Importance of Skeletal Muscle Crosstalk with the Fat Tissue
and the Gut in Protection against Intestinal Disorders. Exer-
cise could improve nutrient metabolism in skeletal muscle
as well as vascular function and microcirculation, but the
accumulated so far evidence suggests that the protective
effect of exercise may to some extent be ascribed to its anti-
inflammatory effect. Exercisemay exert its anti-inflammatory
effect via a reduction in visceral fat mass and/or by induction
of an anti-inflammatory environment with each bout of exer-
cise. Such effects may in part be mediated via muscle-derived
peptides [54]. If the endocrine and paracrine functions of
the muscle are not stimulated through contractions, this
will cause dysfunction of several organs and tissues of the
body as well as an increased risk of chronic inflammatory
diseases [54, 92, 93]. As mentioned before, myokines may
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balance and counteract the effects of adipokines taking part in
crosstalk between skeletal muscle and adipose tissue [37, 54].
The secreted myokines are associated with muscle function
revealing a novel secretory proteins released from skeletal
muscles during exercise that also have been shown to be
impaired with ageing.
The prototype myokine, IL-6, appears to be able to medi-
ate metabolic effects as well as anti-inflammatory effects. In
response to muscle contractions muscle fibres express the
myokine IL-6, which exerts its effects both locally within the
muscle and in several distant organs [54, 94]. It has been
accepted that the rise in IL-6 level was a consequence of
immune response to local damage observed during exercise.
Nowadays it is known that muscle is unique in its ability
to produce IL-6 during contraction in completely TGF-
independent mode. This suggests a major role for this
cytokine in a regulation of metabolism rather than acting as
an inflammatory mediator [95, 96]. It was shown that IL-
6 released by muscle during exercise can mediate release of
GLP-1 from intestinal L cells (and from pancreatic A cells)
which in turn acts as an incretin causing insulin release
providing an evidence that there is possible crosstalk between
adipocytes, muscle, and pancreas responsible for energy
homeostasis [96]. The exercise increased dramatically level
of IL-6 in mice and induced a parallel marked rise in GLP-
1 [96]. Glucagon-like peptides are trophic growth factors that
enhance repair of damaged intestinal mucosa and the release
of these factors could be in part responsible for beneficial
effect of exercise [97–100].
IL-15 that is expressed in human skeletal muscle has been
identified as an anabolic factor inmuscle growth andhas been
implicated in muscle-fat crosstalk [54]. It was demonstrated
that IL-15 mRNA levels were upregulated in human skeletal
muscle following a bout of strength training, suggesting that
IL-15 may accumulate within the muscle as a consequence
of regular training [101]. Interestingly, a decrease in visceral
fat mass, but not subcutaneous fat mass, was observed, when
IL-15 was overexpressed in murine muscle. Also the elevated
circulating levels of IL-15 resulted in significant reductions
in body fat and increased bone mineral content [102, 103].
In a recent study, Bostro¨m and colleagues [104] identified
a new myokine which they called irisin. This myokine is
released during exercise and cause the transformation of
white fat cells into bright cells (brown-in-white fat cells),
with a phenotype similar to that of brown fat cells [104,
105]. In humans, plasma levels of irisin after 10 weeks of
regular endurance training were significantly and markedly
increased. It was suggested that irisin could be therapeutic
for human metabolic disease, obesity, and other disorders in
which the exercise is beneficial [104, 105]. Recently, a new
myokine secreted protein acidic and rich in cysteine (SPARC)
was functionally characterized [93]. SPARC had increased in
skeletal muscle and had been secreted into the circulation in
response to exercise. The release of SPARC was linked with
inhibition of colon tumorigenesis by increasing apoptosis
[106]. SPARC is a secreted matricellular glycoprotein that is
involved in the development, remodeling, and tissue repair
by modulating cell-cell and cell-matrix interactions as well
as other functions such as antitumorigenesis action [106].
Interestingly, a single bout of exercise rapidly increased
SPARC blood plasma and muscle levels suggesting that the
muscle cells secrete this myokine into the circulation. This
exercise-induced increase in SPARC appeared to be muscle-
specific because no increase was observed in other organs
where SPARC was found to be abundant [106].
Depletion of skeletal muscle mass, decreased muscle
strength and endurance, and reduced height velocity in chil-
dren are characteristic features in IBD [2, 107–109]. Particu-
larly in CD, muscle mass and function are reduced compared
to healthy controls, potentially resulting in disability [110].
Mechanisms contributing to muscle impairment and thus
potential therapeutic targets are poorly understood.The IBD-
related growth failure and decreased muscle mass could be
the result of a variety of mechanisms including decreased
nutrient intake, malabsorption of ingested nutrients, and
increased metabolic rate but also could be attributed to ele-
vated concentrations of inflammatory cytokines, decreased
level of insulin-like growth factor 1 (IGF-1), and treatment
with corticosteroids [111]. Both plasma IGF-I and muscle
IGF-I are decreased in response to diverse inflammatory
insults that accelerate the loss of muscle protein [112]. The
function of the GH-insulin-like growth factor- (IGF-) I
axis depends on finely tuned mechanisms, which can be
impaired by inflammatory cytokines released from patho-
logically modified mWAT. Inflammatory cytokines, notably
TNF-𝛼, reduce liver GH receptor numbers and seem to
be responsible for hepatic GH resistance and decrease of
circulating IGF-I level that leads to growth inhibition and
decrease of lean body mass (LBM) [112–114]. Recent study
has shown an attenuated muscle hypertrophy pathway in CD
compared with controls particularly in human subjects with
lower serum vitamin D
3
and lower physical activity indices.
This reduced muscle mass in CD may be explained, in part,
by impaired activation of muscle protein synthesis pathways,
in particular IGF1-Akt pathway. Finally, it was concluded
that the normal vitamin D levels and regular exercise may
be protective in CD [110]. Studies performed on rats with
experimental colitis have demonstrated inhibitory effects of
inflammation on IGF-I generation and the linear growth, the
mechanisms independent ofmalnutrition [115, 116]. Impaired
function of satellite cells is another link between impaired
insulin/IGF-I signaling and muscle protein loss [115]. It was
shown that resistance training can prevent and even reverse
the progression of sarcopenia [117].
Accumulating evidence suggests that peroxisome pro-
liferator-activated receptor 𝛾 coactivator 𝛼 (PGC-1𝛼) and
TWEAK-Fn14 system are key regulators of skeletal muscle
mass in various catabolic states. While the activation of
TWEAK-Fn14 signaling causes muscle wasting, PGC-1𝛼 pre-
serves skeletal muscle mass. Inflammatory reactions during
IBD favor TWEAK-Fn14 system when physical exercise pos-
sibly exhibits a counteractive effect [9, 10, 118, 119].
4.2. Other Benefits of Exercise for IBD Patients. Beside the
anti-inflammatory actions, several other benefits of physical
exercise in IBD patients have been suggested. Ankylosing
spondylitis has been specifically associated with IBD, but
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the exercise therapy improved the flexibility strength and
reduced pain of the joints [120]. IBD is associated with
decreased bone mineral density and increased risk of osteo-
porosis [121] and preventive role of exercise has been pro-
posed [122–124]. It was demonstrated that physical exercise
can increase bone mineral density (BMD) in CD and may
reduce the risk of osteoporotic fracture [122]. The pediatric
patients, particularly with Crohn’s disease, are at risk for extra
intestinal manifestation including growth failure, weight loss,
and anemia. Additional beneficial effect of exercise could be
amelioration of accompanying anorexia, possibly by modi-
fication of the release of adipokines and ghrelin [125]. The
reduced food intake in IBD could be caused by abdominal
pain, diarrhea and incontinence, surgery, nausea, depression,
or a feeling of general unwellness but satiety control in
IBD patients is also probably modulated by availability of
inflammatory cytokines like leptinwhich suppresses appetite,
reducing the motivation to eat [126–128]. The fatigue is a
commonly observed symptom in CD, even in quiescent state
of the disease and this effect is probably mediated, at least
in part, by cytokines [93, 129]. Role of exercise in reduction
of fatigue in chronic diseases including IBD was emphasized
[93, 129, 130]. IBD patients have higher levels of daily stress
and a lower quality of life compared with general population
but also with those patients who suffer from other chronic
diseases [27, 28]. The beneficial role of exercise in such cases
has been proven [131, 132].
The effect of exercise on different immune parameters
could depend on its intensity, duration, and the type of
exercise (e.g., endurance versus resistance training, acute
versus chronic exercise). Systematic exercise may be benefi-
cial for CD patients for its anti-inflammatory and anabolic
properties. However, acute, strenuous exercise could lead to
release of inflammatory cytokines that could be involved
in the pathology of CD and even induce an exacerbated
inflammatory response [24].
Previous studies show that low-intensity exercise is well
tolerated in IBD patients. Moreover, this exerted a beneficial
effect on course of this disease. In guidelines created in 1998
specifically for IBD patients, physical exercise was recom-
mended for general health to counteract muscle wasting and
improve bone density [133]. An aerobic activity for 20min
to 60min two to five days every week, accompanied by
resistance exercise at least twice per week was recommended.
The guidelines, however, were not based on actual research.
In recent review authors proposed similar recommendations
and suggested that two main types of physical interventions
should be recommended for CD patients, namely, the aerobic
activity and the muscular resistance training [23].
4.3. High-Intensity Physical Training in the Treatment of IBD.
Single bouts of exercise could activate the same inflammatory
mediators as those involved in pathology of IBD. It is
generally accepted that high intensity exercise may lead to an
acute although transient, exacerbation of inflammation, and
the symptoms of IBD. Therefore, such training is generally
not recommended for IBD patients [24]. However, such
recommendations are not well supported by research studies.
Only one study which examined the effect of high intensity
intermittent exercise in pediatric patients concluded that that
such intense exercise is well tolerated [44].
The generally accepted model for exercise prescription
in many chronic inflammatory diseases was moderate-
intensity-aerobic continuous training with such proven ben-
efits like increase in exercise capacity, the amelioration of
stress, and an increase in quality of life. Recently, however,
a body of evidence has indicated that high intensity interval
training can be performed safely and lead to similar health
effects compared to longer, continuous exercise and is less
associated with release of inflammatory mediators [134, 135].
Such exercise program may be particularly beneficial for
children with CD, not only to improve exercise capacity, but
also because of anabolic action and stimulation of growth
and development [136, 137]. On the other hand moderate
intensity exercise could be more effective than high intensity
in stimulation of release of myokines as shown by Yeo et al.
[138].
5. Conclusion
Although anti-inflammatory pharmaceutical treatments are
beneficial in reducing IBD symptoms, they are often related
to serious side effects and their efficacy is not complete.
IBD patients continue to have physical and psychological
complaints, impairing their quality of life. Preliminary studies
demonstrate that moderate exercise has no negative health
effects and may diminish some symptoms of IBD. The
exercise is recommended also because it could counteract
some IBD specific complications by improving immunolog-
ical response, psychological health, nutritional status, bone
mineral density and reversing the decrease of muscle mass
and strength. Recent research suggests that the beneficial
effects of regular exercise may be in part due to the anti-
inflammatory effects of myokines released due to skeletal
muscle contractions. Further studies are definitely required
to confirm these observations and establish exercise regimes
for different IBD patient groups. Additional basic and clinical
research with exercise of higher intensities is also needed to
establish a potential acceptable limit for physical activity in
IBD patients.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgment
This paper and own authors data described in this paper were
supported by the Grant from National Center of Science in
Poland (Contract no. NCN-umo-2013/09/B/NZ4/01566).
References
[1] K.M. Beavers, T. E. Brinkley, andB. J. Nicklas, “Effect of exercise
training on chronic inflammation,” Clinica Chimica Acta, vol.
411, no. 11-12, pp. 785–793, 2010.
10 BioMed Research International
[2] F. Shanahan, “Crohn’s disease,” The Lancet, vol. 359, no. 9300,
pp. 62–69, 2002.
[3] J. Terzic´, S. Grivennikov, E. Karin, andM. Karin, “Inflammation
and colon cancer,” Gastroenterology, vol. 138, no. 6, pp. 2101–
2114, 2010.
[4] D. C. Baumgart and W. J. Sandborn, “Inflammatory bowel dis-
ease: clinical aspects and established and evolving therapies,”
The Lancet, vol. 369, no. 9573, pp. 1641–1657, 2007.
[5] R. B. Sartor, “Mechanisms of disease: Pathogenesis of Crohn’s
disease and ulcerative colitis,”Nature Clinical Practice Gastroen-
terology and Hepatology, vol. 3, no. 7, pp. 390–407, 2006.
[6] W. Strober and I. J. Fuss, “Proinflammatory cytokines in the
pathogenesis of inflammatory bowel diseases,” Gastroenterol-
ogy, vol. 140, no. 6, pp. 1756–1767, 2011.
[7] W. Strober, F. Zhang, A. Kitani, I. Fuss, and S. Fichtner-Feigl,
“Proinflammatory cytokines underlying the inflammation of
Crohn’s disease,” Current Opinion in Gastroenterology, vol. 26,
no. 4, pp. 310–317, 2010.
[8] T. Dohi, A. Borodovsky, P. Wu et al., “TWEAK/Fn14 pathway:
a nonredundant role in intestinal damage in mice through a
TWEAK/intestinal epithelial cell axis,” Gastroenterology, vol.
136, no. 3, pp. 912–923, 2009.
[9] T. Dohi and L. C. Burkly, “The TWEAK/Fn14 pathway as an
aggravating and perpetuating factor in inflammatory diseases:
focus on inflammatory bowel diseases,” Journal of Leukocyte
Biology, vol. 92, no. 2, pp. 265–279, 2012.
[10] A. Son, T. Oshio, Y. I. Kawamura et al., “TWEAK/Fn14 pathway
promotes a T helper 2-type chronic colitis with fibrosis inmice,”
Mucosal Immunology, vol. 6, no. 6, pp. 1131–1142, 2013.
[11] L. C. Burkly and T. Dohi, “The TWEAK/Fn14 pathway in tissue
remodeling: for better or for worse,” Advances in Experimental
Medicine and Biology, vol. 691, pp. 305–322, 2011.
[12] C. J. Caspersen, K. E. Powell, and G. Christenson, “Physical
activity, exercise and physical fitness: definitions and distinc-
tions for health-related research,”PublicHealth Reports, vol. 100,
no. 2, pp. 126–131, 1985.
[13] K. R. Wilund, “Is the anti-inflammatory effect of regular exer-
cise responsible for reduced cardiovascular disease?” Clinical
Science, vol. 112, no. 11-12, pp. 543–555, 2007.
[14] L. Hoffman-Goetz and B. K. Pedersen, “Exercise and the im-
mune system: a model of the stress response?” Immunology
Today, vol. 15, no. 8, pp. 382–387, 1994.
[15] B. K. Pedersen and D. C. Nieman, “Exercise immunology:
integration and regulation,” Immunology Today, vol. 19, no. 5,
pp. 204–206, 1998.
[16] L. Fitzgerald, “Exercise and the immune system,” Immunology
Today, vol. 9, no. 11, pp. 337–339, 1988.
[17] S. A. Bartram, R. T. Peaston, D. J. Rawlings, D. Walshaw, R. M.
Francis, andN. P.Thompson, “Mutifactorial analysis of risk fac-
tors for reduced bone mineral density in patients with Crohn’s
disease,” World Journal of Gastroenterology, vol. 12, no. 35, pp.
5680–5686, 2006.
[18] N. P. Walsh, M. Gleeson, D. B. Pyne et al., “Position statement
part two: maintaining immune health,” Exercise Immunology
Review, vol. 17, pp. 64–103, 2011.
[19] N. P. Walsh, M. Gleeson, R. J. Shephard et al., “Position state-
ment. Part one: immune function and exercise,” Exercise Im-
munology Review, vol. 17, pp. 6–63, 2011.
[20] G. W. K. Ho, “Lower gastrointestinal distress in endurance
athletes,” Current Sports Medicine Reports, vol. 8, no. 2, pp. 85–
91, 2009.
[21] J. Kruk and U. Czerniak, “Physical activity and its relation to
cancer risk: updating the evidence,” Asian Pacific Organization
for Cancer Prevention, vol. 14, no. 7, pp. 3993–4003, 2013.
[22] V. Ng, W. Millard, C. Lebrun, and J. Howard, “Exercise and
Crohn’s disease: speculations on potential benefits,” Canadian
Journal of Gastroenterology, vol. 20, no. 10, pp. 657–660, 2006.
[23] C. A. Pe´rez, “Prescription of physical exercise in Crohn’s
disease,” Journal of Crohn’s and Colitis, vol. 3, no. 4, pp. 225–231,
2009.
[24] N.Narula andR.N. Fedorak, “Exercise and inflammatory bowel
disease,”Canadian Journal of Gastroenterology, vol. 22, no. 5, pp.
497–504, 2008.
[25] N. Packer, L. Hoffman-Goetz, and G. Ward, “Does physical
activity affect quality of life, disease symptoms and immune
measures in patients with inflammatory bowel disease? A
systematic review,” Journal of Sports Medicine and Physical
Fitness, vol. 50, no. 1, pp. 1–18, 2010.
[26] J. Cosnes, C. Gowerrousseau, P. Seksik, and A. Cortot, “Epi-
demiology and natural history of inflammatory bowel diseases,”
Gastroenterology, vol. 140, no. 6, pp. 1785–1794, 2011.
[27] T. Lobstein, L. Baur, and R. Uauy, “Obesity in children and
young people: a crisis in public health,” Obesity Reviews, vol. 5,
supplement 1, pp. 4–104, 2004.
[28] A. Sonnenberg, “Occupational distribution of inflammatory
bowel disease among German employees,” Gut, vol. 31, no. 9,
pp. 1037–1040, 1990.
[29] P.-G. Persson, C.-E. Leijonmarck, O. Bernell, G. Hellers, and A.
Ahlbom, “Risk indicators for inflammatory bowel disease,” In-
ternational Journal of Epidemiology, vol. 22, no. 2, pp. 268–272,
1993.
[30] H. Boggild, F. Tuchsen, and E. Orhede, “Occupation, employ-
ment status and chronic inflammatory bowel disease in Den-
mark,” International Journal of Epidemiology, vol. 25, no. 3, pp.
630–637, 1996.
[31] I. Klein, S. Reif, H. Farbstein, A. Halak, and T. Gilat, “Preillness
non dietary factors and habits in inflammatory bowel disease,”
Italian Journal of Gastroenterology and Hepatology, vol. 30, no.
3, pp. 247–251, 1998.
[32] C. Cucino and A. Sonnenberg, “Occupational mortality from
inflammatory bowel disease in theUnited States 1991–1996,”The
American Journal of Gastroenterology, vol. 96, no. 4, pp. 1101–
1105, 2001.
[33] J. Halfvarson, T. Jess, A. Magnuson et al., “Environmental
factors in inflammatory bowel disease: a co-twin control study
of a Swedish-Danish twin population,” Inflammatory Bowel
Diseases, vol. 12, no. 10, pp. 925–933, 2006.
[34] S. S. Chan, R. Luben, A. Olsen et al., “Body mass index and
the risk for Crohn’s disease and ulcerative colitis: data from a
European Prospective Cohort Study (The IBD in EPIC Study),”
The American Journal of Gastroenterology, vol. 108, no. 4, pp.
575–582, 2013.
[35] T. Hlavaty, J. Toth, T. Koller et al., “Smoking, breastfeeding,
physical inactivity, contact with animals, and size of the family
influence the risk of inflammatory bowel disease: a Slovak case-
control study,” United European Gastroenterology Journal, 2013.
[36] H. Khalili, A. N. Ananthakrishnan, G. G. Konijeti et al., “Physi-
cal activity and risk of inflammatory bowel disease: prospective
study from the Nurses’ Health Study cohorts,” British Medical
Journal, vol. 347, 2013.
BioMed Research International 11
[37] J. Bilski, A. I. Mazur-Bialy, M. Wierdak et al., “The impact of
physical activity and nutrition on inflammatory bowel disease:
the potential role of cross talk between adipose tissue and
skeletal muscle,” The Journal of Physiology and Pharmacology,
vol. 64, no. 2, pp. 143–155, 2013.
[38] C. P. Loudon, V. Corroll, J. Butcher, P. Rawsthorne, and C. N.
Bernstein, “The effects of physical exercise on patients with
Crohn’s disease,”The American Journal of Gastroenterology, vol.
94, no. 3, pp. 697–703, 1999.
[39] V. Ng,W.Millard, C. Lebrun, and J. Howard, “Low-intensity ex-
ercise improves quality of life in patients with Crohn’s disease,”
Clinical Journal of Sport Medicine, vol. 17, no. 5, pp. 384–388,
2007.
[40] N. Gupta, S. Khera, R. P. Vempati, R. Sharma, and R. L. Bijlani,
“Effect of yoga based lifestyle intervention on state and trait
anxiety,” Indian Journal of Physiology and Pharmacology, vol. 50,
no. 1, pp. 41–47, 2006.
[41] I. Nathan, C. Norton, W. Czuber-Dochan et al., “Exercise in
individuals with inflammatory bowel disease,”Gastroenterology
Nursing, vol. 36, no. 6, pp. 437–442, 2013.
[42] R. D’Inca`, M. Varnier, C. Mestriner, D. Martines, A. D’Odorico,
andG. C. Sturniolo, “Effect ofmoderate exercise onCrohn’s dis-
ease patients in remission,” Italian Journal of Gastroenterology
and Hepatology, vol. 31, no. 3, pp. 205–210, 1999.
[43] S. T. Nic, T. C. Raftery, O. McMahon et al., “High prevalence
of overweight and obesity in adults with Crohn’s disease:
associations with disease and lifestyle factors,” Journal of Crohn’s
and Colitis, vol. 7, no. 7, pp. e241–e248, 2013.
[44] H. Ploeger, J. Obeid, T. Nguyen et al., “Exercise and inflamma-
tion in pediatric Crohn’s disease,” International Journal of Sports
Medicine, vol. 33, no. 8, pp. 671–679, 2012.
[45] D. Chan, H. Robbins, S. Rogers et al., “Inflammatory bowel
disease and exercise: results of a Crohn’s and Colitis UK survey,”
Frontline Gastroenterology, vol. 5, no. 1, pp. 44–48, 2014.
[46] M. D. Cook, S. A. Martin, C. Williams et al., “Forced treadmill
exercise training exacerbates inflammation and causes mor-
tality while voluntary wheel training is protective in a mouse
model of colitis,” Brain, Behavior, and Immunity, pp. 46–56,
2013.
[47] X.-Z. Shi, J. H. Winston, and S. K. Sarna, “Differential immune
and genetic responses in rat models of Crohn’s colitis and ulcer-
ative colitis,” American Journal of Physiology: Gastrointestinal
and Liver Physiology, vol. 300, no. 1, pp. G41–G51, 2011.
[48] A. Saxena, E. Fletcher, B. Larsen et al., “Effect of exercise
on chemically-induced colitis in adiponectin deficient mice,”
Journal of Inflammation, vol. 9, no. 1, article 30, 2012.
[49] L. Hoffman-Goetz, N. Pervaiz, N. Packer, and J. Guan, “Free-
wheel training decreases pro- and increases anti-inflammatory
cytokine expression in mouse intestinal lymphocytes,” Brain,
Behavior, and Immunity, vol. 24, no. 7, pp. 1105–1115, 2010.
[50] L. Hoffman-Goetz, R. J. Thorne, and M. E. Houston, “Splenic
immune responses following treadmill exercise in mice,” Cana-
dian Journal of Physiology and Pharmacology, vol. 66, no. 11, pp.
1415–1419, 1988.
[51] L. Hoffman-Goetz, P. A. Spagnuolo, and J. Guan, “Repeated ex-
ercise in mice alters expression of IL-10 and TNF-𝛼 in intestinal
lymphocytes,” Brain, Behavior, and Immunity, vol. 22, no. 2, pp.
195–199, 2008.
[52] B. Luo, D. Xiang, D. C. Nieman et al., “The effects of moderate
exercise on chronic stress-induced intestinal barrier dysfunc-
tion and antimicrobial defense,” Brain, Behavior, and Immunity,
2013.
[53] M. D. Kappelman, S. L. Rifas-Shiman, K. Kleinman et al., “The
prevalence and geographic distribution of Crohn’s disease and
ulcerative colitis in the United States,” Clinical Gastroenterology
and Hepatology, vol. 5, no. 12, pp. 1424–1429, 2007.
[54] B. K. Pedersen and M. A. Febbraio, “Muscles, exercise and
obesity: skeletal muscle as a secretory organ,” Nature Reviews
Endocrinology, vol. 8, no. 8, pp. 457–465, 2012.
[55] A. L. Sheehan, B. F. Warren, M. W. L. Gear, and N. A. Shep-
herd, “Fat-wrapping in Crohn’s disease: pathological basis and
relevance to surgical practice,” British Journal of Surgery, vol. 79,
no. 9, pp. 955–958, 1992.
[56] L. Peyrin-Biroulet, F. Gonzalez, L. Dubuquoy et al., “Mesenteric
fat as a source of C reactive protein and as a target for bacterial
translocation in Crohn’s disease,” Gut, vol. 61, no. 1, pp. 78–85,
2012.
[57] L. Peyrin-Biroulet, M. Chamaillard, F. Gonzalez et al., “Mesen-
teric fat in Crohn’s disease: a pathogenetic hallmark or an
innocent bystander?” Gut, vol. 56, no. 4, pp. 577–583, 2007.
[58] A.Kaser andH. Tilg, ““Metabolic aspects” in inflammatory bow-
el diseases,” Current Drug Delivery, vol. 9, no. 4, pp. 326–332,
2012.
[59] A. Batra, M. M. Heimesaat, S. Bereswill et al., “Mesenteric
fat-control site for bacterial translocation in colitis?” Mucosal
Immunology, vol. 5, no. 5, pp. 580–591, 2012.
[60] C. Fink, I. Karagiannides, K. Bakirtzi, and C. Pothoulakis,
“Adipose tissue and inflammatory bowel disease pathogenesis,”
Inflammatory Bowel Diseases, vol. 18, no. 8, pp. 1550–1557, 2012.
[61] M. Drouet, L. Dubuquoy, P. Desreumaux, and B. Bertin,
“Visceral fat and gut inflammation,”Nutrition, vol. 28, no. 2, pp.
113–117, 2012.
[62] S. C. Acedo, E´. M. F. Gotardo, J. M. Lacerda, C. C. de Oliveira,
P. de Oliveira Carvalho, and A. Gambero, “Perinodal adipose
tissue andmesenteric lymph node activation during reactivated
TNBS-colitis in rats,”Digestive Diseases and Sciences, vol. 56, no.
9, pp. 2545–2552, 2011.
[63] L. I. Kredel, A. Batra, T. Stroh et al., “Adipokines from local fat
cells shape the macrophage compartment of the creeping fat in
Crohn’s disease,” Gut, vol. 62, no. 6, pp. 852–862, 2013.
[64] S. H. Jung, A. Saxena, K. Kaur et al., “The role of adipose tissue-
associatedmacrophages and T lymphocytes in the pathogenesis
of inflammatory bowel disease,”Cytokine, vol. 61, no. 2, pp. 459–
468, 2013.
[65] G. Monteleone, F. Pallone, and T. T. MacDonald, “Emerging
immunological targets in inflammatory bowel disease,” Current
Opinion in Pharmacology, vol. 11, no. 6, pp. 640–645, 2011.
[66] T. T. MacDonald, I. Monteleone, M. C. Fantini, and G. Mon-
teleone, “Regulation of homeostasis and inflammation in the
intestine,” Gastroenterology, vol. 140, no. 6, pp. 1768–1775, 2011.
[67] A. M. Mowat and C. C. Bain, “Mucosal macrophages in in-
testinal homeostasis and inflammation,” Journal of Innate Im-
munity, vol. 3, no. 6, pp. 550–564, 2011.
[68] I. C. Roberts-Thomson, J. Fon, W. Uylaki, A. G. Cummins,
and S. Barry, “Cells, cytokines and inflammatory bowel disease:
a clinical perspective,” Expert Review of Gastroenterology and
Hepatology, vol. 5, no. 6, pp. 703–716, 2011.
[69] J. H. Cho, “The genetics and immunopathogenesis of inflamma-
tory bowel disease,” Nature Reviews Immunology, vol. 8, no. 6,
pp. 458–466, 2008.
[70] G. Shelley-Fraser, N. R. Borley, B. F. Warren, and N. A. Shep-
herd, “The connective tissue changes of Crohn’s disease,”
Histopathology, 2011.
12 BioMed Research International
[71] N. R. Borley,N. J.Mortensen,D. P. Jewell et al., “The relationship
between inflammatory and serosal connective tissue changes in
ileal Crohn’s disease: evidence for a possible causative link,”The
Journal of Pathology, vol. 190, no. 2, pp. 196–202, 2000.
[72] I. Olivier, V. The´odorou, P. Valet et al., “Is Crohn’s creeping fat
an adipose tissue?” Inflammatory Bowel Diseases, vol. 17, no. 3,
pp. 747–757, 2011.
[73] S. J. McCaskey, E. A. Rondini, I. M. Langohr, and J. I. Fen-
ton, “Differential effects of energy balance on experimentally-
induced colitis,” World Journal of Gastroenterology, vol. 18, no.
7, pp. 627–636, 2012.
[74] V. Ponemone, A. Keshavarzian, M. I. Brand et al., “Apoptosis
and inflammation: role of adipokines in inflammatory bowel
disease,” Clinical and Translational Gastroenterology, vol. 1, no.
10, article e1, 2010.
[75] G. Biesiada, J. Czepiel, A. Ptak-Belowska et al., “Expression
and release of leptin and proinflammatory cytokines in patients
with ulcerative colitis and infectious diarrhea,” The Journal of
Physiology and Pharmacology, vol. 63, no. 5, pp. 471–481, 2012.
[76] M. Barbier, H. Vidal, P. Desreumaux et al., “Overexpression
of leptin mRNA in mesenteric adipose tissue in inflammatory
bowel diseases,”Gastroenterologie Clinique et Biologique, vol. 27,
no. 11, pp. 987–991, 2003.
[77] M. Barbier, C. Cherbut, A. C. Aube´, H. M. Blottie`re, and J. P.
Galmiche, “Elevated plasma leptin concentrations in early sta-
ges of experimental intestinal inflammation in rats,” Gut, vol.
43, no. 6, pp. 783–790, 1998.
[78] U. P. Singh, N. P. Singh, H. Guan et al., “Leptin antagonist amel-
iorates chronic colitis in IL-10-/-mice,” Immunobiology, vol. 218,
no. 12, pp. 1439–1451, 2013.
[79] K. Yamamoto, T. Kiyohara, Y. Murayama et al., “Production
of adiponectin, an anti-inflammatory protein, in mesenteric
adipose tissue in Crohn’s disease,” Gut, vol. 54, no. 6, pp. 789–
796, 2005.
[80] V. S. Rodrigues, M. Milanski, J. J. Fagundes et al., “Serum levels
and mesenteric fat tissue expression of adiponectin and leptin
in patients with Crohn’s disease,” Clinical & Experimental
Immunology, vol. 170, no. 3, pp. 358–364, 2012.
[81] M. Chandran, S. A. Phillips, T. Ciaraldi, and R. R. Henry,
“Adiponectin: more than just another fat cell hormone?” Dia-
betes Care, vol. 26, no. 8, pp. 2442–2450, 2003.
[82] A. Schaffler, J. Scholmerich, and C. Buchler, “Mechanisms of
disease: adipocytokines and visceral adipose tissue—emerging
role in intestinal and mesenteric diseases,” Nature Clinical
Practice Gastroenterology & Hepatology, vol. 2, no. 2, pp. 103–
111, 2005.
[83] A. Scha¨ffler and H. Herfarth, “Creeping fat in Crohn’s disease:
travelling in a creeper lane of research,” Gut, vol. 54, no. 6, pp.
742–744, 2005.
[84] J. Weigert, F. Obermeier, M. Neumeier et al., “Circulating levels
of chemerin and adiponectin are higher in ulcerative colitis and
chemerin is elevated in Crohn’s disease,” Inflammatory Bowel
Diseases, vol. 16, no. 4, pp. 630–637, 2010.
[85] L. Valentini, E. K. Wirth, U. Schweizer et al., “Circulating adi-
pokines and the protective effects of hyperinsulinemia in in-
flammatory bowel disease,”Nutrition, vol. 25, no. 2, pp. 172–181,
2009.
[86] K.Karmiris, I. E. Koutroubakis, andE.A.Kouroumalis, “Leptin,
adiponectin, resistin, and ghrelin—implications for inflamma-
tory bowel disease,”Molecular Nutrition and Food Research, vol.
52, no. 8, pp. 855–866, 2008.
[87] A. Scha¨ffler and J. Scho¨lmerich, “The role of adiponectin in in-
flammatory gastrointestinal diseases,” Gut, vol. 58, no. 3, pp.
317–322, 2009.
[88] A. Scha¨ffler, J. Scholmerich, and C. Buchler, “Mechanisms of dis
ease: adipocytokines and visceral adipose tissue—emerging
role in intestinal and mesenteric diseases,” Nature Reviews
Gastroenterology and Hepatology, vol. 2, no. 2, pp. 103–111, 2005.
[89] A. Zulian, R. Cancello, G.Micheletto et al., “Visceral adipocytes:
old actors in obesity and new protagonists in Crohn’s disease?”
Gut, vol. 61, no. 1, pp. 86–94, 2012.
[90] G. Paul, A. Scha¨ffler, M. Neumeier et al., “Profiling adipocy-
tokine secretion from creeping fat in Crohn’s disease,” Inflam-
matory Bowel Diseases, vol. 12, no. 6, pp. 471–477, 2006.
[91] K. Karmiris, I. E. Koutroubakis, and E. A. Kouroumalis, “The
emerging role of adipocytokines as inflammatory mediators in
inflammatory bowel disease,” Inflammatory Bowel Diseases, vol.
11, no. 9, pp. 847–855, 2005.
[92] A. Bortoli, N. Pedersen, D. Duricova et al., “Pregnancy outcome
in inflammatory bowel disease: prospective European case-
control ECCO-EpiCom study, 2003–2006,” Alimentary Phar-
macology andTherapeutics, vol. 34, no. 7, pp. 724–734, 2011.
[93] B. K. Pedersen and B. Saltin, “Evidence for prescribing exercise
as therapy in chronic disease,” Scandinavian Journal of Medicine
and Science in Sports, vol. 16, no. 1, pp. 3–63, 2006.
[94] M. A. Febbraio, S. Rose-John, and B. K. Pedersen, “Is inter-
leukin-6 receptor blockade the holy grail for inflammatory
diseases?” Clinical Pharmacology and Therapeutics, vol. 87, no.
4, pp. 396–398, 2010.
[95] C. Keller, Y. Hellsten, A. Steensberg, and B. Klarlund Pedersen,
“Differential regulation of IL-6 and TNF-𝛼 via calcineurin in
human skeletal muscle cells,” Cytokine, vol. 36, no. 3-4, pp. 141–
147, 2006.
[96] H. Ellingsgaard, I. Hauselmann, B. Schuler et al., “Interleukin-6
enhances insulin secretion by increasing glucagon-like peptide-
1 secretion from L cells and alpha cells,”NatureMedicine, vol. 17,
no. 11, pp. 1481–1489, 2011.
[97] P. L. Brubaker and D. J. Drucker, “Minireview: glucagon-
like peptides regulate cell proliferation and apoptosis in the
pancreas, gut, and central nervous system,” Endocrinology, vol.
145, no. 6, pp. 2653–2659, 2004.
[98] D. J. Drucker, B. Yusta, R. P. Boushey, L. DeForest, and P. L.
Brubaker, “Human [Gly2]GLP-2 reduces the severity of colonic
injury in a murine model of experimental colitis,” American
Journal of Physiology: Gastrointestinal and Liver Physiology, vol.
276, no. 1, pp. G79–G91, 1999.
[99] M. S. Geier, D. Tenikoff, R. Yazbeck, G. W. McCaughan, C. A.
Abbott, and G. S. Howarth, “Development and resolution of
experimental colitis inmice with targeted deletion of dipeptidyl
peptidase IV,” Journal of Cellular Physiology, vol. 204, no. 2, pp.
687–692, 2005.
[100] R. Yazbeck, G. S. Howarth, M. S. Geier, H.-U. Demuth, and
C. A. Abbott, “Inhibiting dipeptidyl peptidase activity partially
ameliorates colitis in mice,” Frontiers in Bioscience, vol. 13, no.
18, pp. 6850–6858, 2008.
[101] A. R. Nielsen, R. Mounier, P. Plomgaard et al., “Expression of
interleukin-15 in human skeletal muscle—effect of exercise and
muscle fibre type composition,” The Journal of Physiology, vol.
584, no. 1, pp. 305–312, 2007.
BioMed Research International 13
[102] L. S. Quinn, B. G. Anderson, L. Strait-Bodey, A. M. Stroud,
and J. M. Argue´s, “Oversecretion of interleukin-15 from skeletal
muscle reduces adiposity,” American Journal of Physiology:
Endocrinology and Metabolism, vol. 296, no. 1, pp. E191–E202,
2009.
[103] L. S. Quinn, L. Strait-Bodey, B. G. Anderson, J. M. Argile´s, and
P. J. Havel, “Interleukin-15 stimulates adiponectin secretion
by 3T3-L1 adipocytes: Evidence for a skeletal muscle-to-fat
signaling pathway,” Cell Biology International, vol. 29, no. 6, pp.
449–457, 2005.
[104] P. Bostro¨m, J. Wu, M. P. Jedrychowski et al., “A PGC1-𝛼-
dependent myokine that drives brown-fat-like development of
white fat and thermogenesis,” Nature, vol. 481, no. 7382, pp.
463–468, 2012.
[105] P. A. Bostrom, E. L. Graham, A. Georgiadi et al., “Impact of ex-
ercise on muscle and nonmuscle organs,” IUBMB Life, vol. 65,
no. 10, pp. 845–850, 2013.
[106] W. Aoi, Y. Naito, T. Takagi et al., “A novel myokine, secreted
protein acidic and rich in cysteine (SPARC), suppresses colon
tumorigenesis via regular exercise,” Gut, vol. 62, no. 6, pp. 882–
889, 2013.
[107] R. Vadan, L. S. Gheorghe, A. Constantinescu, and C. Gheorghe,
“Theprevalence ofmalnutrition and the evolution of nutritional
status in patients with moderate to severe forms of Crohn’s
disease treated with Infliximab,” Clinical Nutrition, vol. 30, no.
1, pp. 86–91, 2011.
[108] J.-B. Wiroth, J. Filippi, S. M. Schneider et al., “Muscle perfor-
mance in patients with Crohn’s disease in clinical remission,”
Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 296–303, 2005.
[109] S. Schneider, R. Al-Jaouni, J. Filippi et al., “Sarcopenia is prev-
alent in patients with Crohn’s disease in clinical remission,” In-
flammatory Bowel Diseases, vol. 14, no. 11, pp. 1562–1568, 2008.
[110] D. R. van Langenberg, P. D. Gatta, B. Hill et al., “Delving into
disability in Crohn’s disease: dysregulation of molecular path-
ways may explain skeletal muscle loss in Crohn’s disease,”
Journal of Crohn’s and Colitis, 2013.
[111] R. Shamir, M. Phillip, and A. Levine, “Growth retardation in
pediatric Crohn’s disease: pathogenesis and interventions,” In-
flammatory Bowel Diseases, vol. 13, no. 5, pp. 620–628, 2007.
[112] R. A. Frost andC.H. Lang, “Alteration of somatotropic function
by proinflammatory cytokines,” Journal of Animal Science, vol.
82, pp. E100–E109, 2004.
[113] R. A. Frost, G. J. Nystrom, L. S. Jefferson, and C. H. Lang, “Hor-
mone, cytokine, and nutritional regulation of sepsis-induced
increases in atrogin-1 and MuRF1 in skeletal muscle,” American
Journal of Physiology: Endocrinology and Metabolism, vol. 292,
no. 2, pp. E501–E512, 2007.
[114] C. H. Lang, L. Hong-Brown, and R. A. Frost, “Cytokine in-
hibition of JAK-STAT signaling: a new mechanism of growth
hormone resistance,” Pediatric Nephrology, vol. 20, no. 3, pp.
306–312, 2005.
[115] A. Ballinger, “Fundamental mechanisms of growth failure in
inflammatory bowel disease,” Hormone Research, vol. 58, no. 1,
pp. 7–10, 2002.
[116] A. B. Ballinger, O. Azooz, T. El-Haj, S. Poole, and M. J. G.
Farthing, “Growth failure occurs through a decrease in insulin-
like growth factor 1 which is independent of undernutrition in
a rat model of colitis,” Gut, vol. 46, no. 5, pp. 694–700, 2000.
[117] L. B. Verdijk, B. G. Gleeson, R. A. M. Jonkers et al., “Skeletal
muscle hypertrophy following resistance training is accompa-
nied by a fiber type-specific increase in satellite cell content in
elderly men,” Journals of Gerontology A, vol. 64, no. 3, pp. 332–
339, 2009.
[118] S. M. Hindi, V.Mishra, S. Bhatnagar et al., “Regulatory circuitry
of TWEAK-Fn14 system and PGC-1a in skeletal muscle atrophy
program,”The FASEB Journal, vol. 28, no. 3, pp. 1398–1411, 2013.
[119] M. M. Tajrishi, T. S. Zheng, L. C. Burkly et al., “The TWEAK-
Fn14 pathway: a potent regulator of skeletal muscle biology in
health and disease,” Cytokine & Growth Factor Reviews, 2013.
[120] Z. Uhrin, S. Kuzis, and M. M. Ward, “Exercise and changes in
health status in patients with ankylosing spondylitis,” Archives
of Internal Medicine, vol. 160, no. 19, pp. 2969–2975, 2000.
[121] J. S. Siffledeen, K. Siminoski, H. Jen, and R. N. Fedorak,
“Vertebral fractures and role of low bone mineral density in
Crohn’s disease,” Clinical Gastroenterology and Hepatology, vol.
5, no. 6, pp. 721–728, 2007.
[122] R. J. Robinson, T. Krzywicki, L. Almond et al., “Effect of a low-
impact exercise program on bone mineral density in Crohn’s
disease: a randomized controlled trial,” Gastroenterology, vol.
115, no. 1, pp. 36–41, 1998.
[123] N. Lee, G. L. Radford-Smith, M. Forwood, J. Wong, and D. R.
Taaffe, “Body composition and muscle strength as predictors of
bone mineral density in Crohn’s disease,” Journal of Bone and
Mineral Metabolism, vol. 27, no. 4, pp. 456–463, 2009.
[124] N. Lee, G. Radford-Smith, and D. R. Taaffe, “Bone loss in
Crohn’s disease: exercise as a potential countermeasure,” Inflam-
matory Bowel Diseases, vol. 11, no. 12, pp. 1108–1118, 2005.
[125] J. Bilski, G. Manko, T. Brzozowski et al., “Effects of exercise of
different intensity on gut peptides, energy intake and appetite
in young males,” Annals of Agricultural and Environmental
Medicine, vol. 20, no. 4, pp. 787–793, 2013.
[126] J. Jaworek, J. Bonior, S. J. Konturek, J. Bilski, A. Szlachcic, andW.
W. Pawlik, “Role of leptin in the control of postprandial
pancreatic enzyme secretion,” The Journal of Physiology and
Pharmacology, vol. 54, no. 4, pp. 591–602, 2003.
[127] Z. Warzecha, A. Dembin´ski, P. Ceranowicz et al., “Influence of
leptin administration on the course of acute ischemic pancre-
atitis,”The Journal of Physiology and Pharmacology, vol. 53, no.
4, pp. 775–790, 2002.
[128] A. Ballinger, “Divergency of leptin response in intestinal inflam-
mation,” Gut, vol. 44, no. 5, pp. 588–589, 1999.
[129] I. M. Minderhoud, M. Samsom, and B. Oldenburg, “Crohn’s
disease, fatigue, and infliximab: is there a role for cytokines in
the pathogenesis of fatigue?”World Journal of Gastroenterology,
vol. 13, no. 14, pp. 2089–2093, 2007.
[130] D. R. van Langenberg and P. R. Gibson, “Factors associated with
physical and cognitive fatigue in patients with Crohn’s Disease:
a cross-sectional and longitudinal Study,” Inflammatory Bowel
Diseases, vol. 20, no. 1, pp. 115–125, 2014.
[131] F. Blondel-Kucharski, C. Chircop, P. Marquis et al., “Health-
related quality of life in Crohn’s disease: a prospective longitu-
dinal study in 231 patients,” The American Journal of Gastroen-
terology, vol. 96, no. 10, pp. 2915–2920, 2001.
[132] I. M. Minderhoud, B. Oldenburg, J. A. Wismeijer, G. P. van
Berge Henegouwen, and A. J. P. M. Smout, “IBS-like symptoms
in patients with inflammatory bowel disease in remission;
relationships with quality of life and coping behavior,”Digestive
Diseases and Sciences, vol. 49, no. 3, pp. 469–474, 2004.
14 BioMed Research International
[133] E. Ball, “Exercise guidelines for patients with inflammatory
bowel disease,” Gastroenterology Nursing, vol. 21, no. 3, pp. 108–
111, 1998.
[134] M. J. Gibala, J. P. Little, M. J. Macdonald, and J. A. Hawley,
“Physiological adaptations to low-volume, high-intensity inter-
val training in health and disease,”The Journal of Physiology, vol.
590, no. 5, pp. 1077–1084, 2012.
[135] K. A. Burgomaster, K. R. Howarth, S. M. Phillips et al., “Similar
metabolic adaptations during exercise after low volume sprint
interval and traditional endurance training in humans,” The
Journal of Physiology, vol. 586, no. 1, pp. 151–160, 2008.
[136] I. Janssen and A. G. LeBlanc, “Systematic review of the health
benefits of physical activity and fitness in school-aged children
and youth,” International Journal of Behavioral Nutrition and
Physical Activity, vol. 7, article 40, 2010.
[137] W. J. Tremaine, L. J. Timmons, E. V. Loftus Jr. et al., “Age at onset
of inflammatory bowel disease and the risk of surgery for
non-neoplastic bowel disease,” Alimentary Pharmacology and
Therapeutics, vol. 25, no. 12, pp. 1435–1441, 2007.
[138] N. H. Yeo, J. Woo, K. O. Shin et al., “The effects of different
exercise intensity on myokine and angiogenesis factors,” The
Journal of Sports Medicine and Physical Fitness, vol. 52, no. 4,
p. 448, 2012.
[139] S. Elsenbruch, J. Langhorst, K. Popkirowa et al., “Effects of
mind-body therapy on quality of life and neuroendocrine and
cellular immune functions in patients with ulcerative colitis,”
Psychotherapy and Psychosomatics, vol. 74, no. 5, pp. 277–287,
2005.
